C12N 2710/16632
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2710/16632 (Use of virus as therapeutic agent, other than vaccine) appears on 159 US grants and 299 published applications in this corpus.
Search patents in C12N- Granted patents
- 159
- Published applications
- 299
- Assignees
- 143
- Inventors
- 391
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 3 | 8 |
| 2003 | 3 | 5 |
| 2004 | 5 | 9 |
| 2005 | 1 | 7 |
| 2006 | 3 | 2 |
| 2007 | 3 | 7 |
| 2008 | 2 | 6 |
| 2009 | 1 | 7 |
| 2010 | 7 | 7 |
| 2011 | 3 | 11 |
| 2012 | 5 | 6 |
| 2013 | 7 | 9 |
| 2014 | 7 | 3 |
| 2015 | 4 | 9 |
| 2016 | 1 | 7 |
| 2017 | 6 | 9 |
| 2018 | 4 | 12 |
| 2019 | 14 | 19 |
| 2020 | 14 | 29 |
| 2021 | 6 | 23 |
| 2022 | 13 | 26 |
| 2023 | 4 | 20 |
| 2024 | 11 | 19 |
| 2025 | 15 | 26 |
| 2026 | 14 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- Stable frozen virus formulation11 Aug 2026US 12,702,688 B2Amgen Inc.
- Oncolytic virus therapy2 Jun 2026US 12,642,832 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Recombinant oncolytic virus, preparation method therefor, use thereof and medicine thereof26 May 2026US 12,636,329 B2
- Oncolytic virus compositions and methods for the treatment of cancer26 May 2026US 12,637,510 B2City of Hope
- Recombinant herpes simplex virus with il-12 expression8 Oct 2026US 2026/0308219 A1
- Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use24 Sep 2026US 2026/0286317 A1The Brigham and Women S Hospital, Inc.
- Use of oncolytic viruses for the treatment of cancer24 Sep 2026US 2026/0286393 A1Amgen Inc.
- Oncolytic viruses to treat brain cancer20 Aug 2026US 2026/0242824 A1The Brigham and Women S Hospital, Inc.
- Herpesviral combination therapy for targeting cancer cells and cancer associated stromal cells11 Jun 2026US 2026/0158087 A1Mayo Foundation for Medical Education and Research
Most cited
By later US patents
- Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject132US 6,428,968 B1The Trustees of the University of Pennsylvania · 2002
- Virus strains63US 7,537,924 B2Biovex Limited · 2009
- Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth41US 6,723,316 B2Onyx Pharmaceuticals, Inc. · 2004
- Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response41US 7,731,952 B2New York University · 2010
- Herpes virus strains for gene therapy40US 7,223,593 B2Biovex Limited · 2007